An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...

A new vaccine for kidney cancer shows excellent preliminary results. All patients on the trial had no evidence of cancer ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...

Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping ...

A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

Fortress Biotech, Helocyte have announced the dosing of the first subject in the trial of Triplex for individuals who are ...

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.

A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

Fortress Biotech and its subsidiary Helocyte have announced the dosing of the first subject in a multi-centre Phase II trial of the cytomegalovirus (CMV) vaccine, Triplex, for individuals who are ...